Category: Healthcare and Pharmaceutical

Implantable Medical Device Tombstone

Lucite tombstone marking equity financing of Minneapolis-based CVRx, a medical device maker.The company produces an implantable device to treat high blood pressure and heart failure.

(6ADL737)
1 Image

Medical Device Developer Tombstone

Lucite tombstone marking the acquisition of Blockade Medical by Balt International. Blockade develops endovascular, catheter-based devices for the treatment of cerebral aneurysms.

(6ALJC03)
1 Image

Custom Lucite with Embedded Pills

Custom Lucite with embedded pills marking the acquisition by Peruvian pharmacy operator Mifarma of Albis Capital.  (6AGP86)

1 Image

Healthcare Provider Deal Toy

Lucite deal toy commemorating the sale by Advent International of its stake in CARE Hospitals, based in Hyderabad, India.

(6LACA37)
1 Image

Pill-Themed Financial Tombstone (Back View)

Back view of pill-themed financial tombstone marking the purchase of New Zealand Pharmaceuticals (NZD). The acquirer was Australian private equity firm Archer Capital.

(6ALR257)
2 Images
Pill-shaped Lucite tombstone commemorating the acquisition of New Zealand Pharmaceuticals by Sydney-based Archer Capital. NZD is a specialty chemicals manufacturer headquartered in Palmerston North.

Fitness-Themed Lucite Tombstone

Fitness-themed Lucite tombstone marking the acquisition of Cybex International, a manufacturer of commercial fitness equipment, including cardiovascular and strength products. Cybex is based in Medway, Massachusetts.

(6ADL583)
1 Image

McKesson Pill-Themed Deal Toy

Pill-themed deal toy marking related pharmaceutical and healthcare transactions involving McKesson and Celesio.

(6LACC85)
1 Image

Pill/Tablet-Themed Deal Toy

Pill/tablet themed deal toy marking the sale by Bayer Korea of the drug Mercilon.

(6LACB53)
1 Image

Commemorative For Research & Development Joint Venture

Lucite commemorative marking a research and development joint venture between Massachusetts-based CRISPR, and German drug company Bayer. The collaboration will center on CRISPR’s gene-editing technology, and focus on the treatment of conditions such as congenital heart disease, blood disorders, and blindness.

(6AGP903)
1 Image